Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Indian parliamentary committee recommends price caps for all drugs

(Reuters) – An Indian parliamentary committee has recommended that price caps should be extended to all drugs in the country and that the government should expedite the capping process. Indian law allows the National Pharmaceutical Pricing Authority (NPPA) regulator to fix prices of drugs on a list of essential medicines, thereby keeping prices in check […]

Read More »

GlaxoSmithKline Recalls Flu Vaccine Over Potency Issues

U.K.-based GlaxoSmithKline (GSK) announced on April 14, 2015 that it was recalling all remaining lots of its 2014-2015 Flulaval Quadrivalent flu vaccine. The company noted that two of the components of the vaccine, the B strains, appeared to have lost potency below the minimum specifications. The potency issue, according to the company, the U.S. Centers […]

Read More »

Oasmia’s Lead Cancer Product Paclical Receives Market Approval in the Russian Federation

UPPSALA, Sweden, April 20, 2015 /PRNewswire/ — Paclical, a novel formulation of paclitaxel based on Oasmia’s XR-17 technology, was approved for treatment of (i.e., it received market authorization for) epithelial ovarian cancer in combination with carboplatin. XR-17 is non-toxic and forms water soluble nanoparticles with paclitaxel.      (Logo: http://photos.prnewswire.com/prnh/20150420/740096 )  The Russia-based company Pharmasyntez holds the […]

Read More »

Lupin Launches Zaxine in Canada

MUMBAI and MONTREAL, April 20, 2015 /PRNewswire/ — Zaxine 550mg (rifaximin) is a long term antibiotic treatment for adults living with hepatic encephalopathy (HE), a complication of liver disease (cirrhosis). HE can lead to a wide spectrum of mental and physical symptoms, including confusion, disruption in sleep patterns, personality changes and coma Zaxine® 550mg has approved by […]

Read More »

Teva to pay $512 million to settle claims of delayed generic Provigil

(Reuters) – Teva Pharmaceutical Industries Ltd has agreed to pay $512 million to settle a class action claiming that Cephalon Inc, which Teva bought in 2011, used anticompetitive settlements to delay generic versions of its wakefulness drug Provigil, according to court papers. The settlement is the largest ever to be paid to drug buyers that […]

Read More »

Merck Cancer Drug Shines Against Skin, Lung Cancer

Merck’s immune-boosting cancer drug, Keytruda, bested the standard of care in advanced melanoma, the deadly skin cancer, and showed promising results in non-small cell lung cancer. Based on these data, Merck says it has filed an application with the Food and Drug Administration for Keytruda to be used in non-small cell lung cancer, and will soon […]

Read More »

Opiate overdoses fall after debut of abuse-resistant OxyContin

(Reuters Health) – Opiate prescriptions and overdoses in the U.S. have declined since the debut of an abuse-resistant version of the painkiller OxyContin and the market withdrawal of the narcotic Darvon, a study finds. Researchers reviewed insurance claims records with data on prescriptions and hospitalizations for more than 30 million adults covered by UnitedHealthCare from […]

Read More »

Merck Announces Submission of Supplemental Biologics License Application to U.S. FDA for KEYTRUDA in Advanced Non-Small Cell Lung Cancer

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of advanced non-small cell lung cancer (NSCLC). KEYTRUDA previously received Breakthrough Therapy […]

Read More »

Teva shares slide on generic Copaxone fears

(Reuters) – Teva Pharmaceutical Industries shares slid five percent on Sunday after U.S. regulators approved a generic version of its top-selling multiple sclerosis drug and amid reports it was mulling a bid for rival Mylan. Teva’s Tel Aviv shares fell to 249.80 shekels ($64) late on Sunday, the first day of trading since both news […]

Read More »

Bristol’s Opdivo proves effective against second type of lung cancer

A large study of Bristol-Myers Squibb Co’s Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications. The U.S. drugmaker on Friday said the study, called Checkmate-057, […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom